Benzinga | Aug 4, 2021 05:00PM EDT

Adaptive Biotechnologies Revises FY21 Sales Guidance From $145M-$155M To $148M-$155M vs $150.16M Est.

Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue. This compares to Adaptive Biotechnologies' previous outlook of $145 million to $155 million.